Study #2020-1245
A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ALLO-316 Following ALLO-647 Containing Regimen in Subjects with Advanced or Metastatic clear Cell Renal Cell Carcinoma (ccRCC)
MD Anderson Study Status
Enrolling
Treatment Agent
ALLO-647, Fludarabine, Cyclophosphamide
Description
This is a Phase 1 dose escalation study following a 3+3 study design. The purpose of the TRAVERSE study is to assess the safety, efficacy, and cell kinetics of ALLO-316 in adults with advanced or metastatic clear cell renal cell carcinoma after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, and ALLO-647 to define a Phase 2 dose.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced/Metastatic Clear Cell Renal Cell Carcinoma
Study phase:
Phase I
Physician name:
Samer Srour
Department:
Stem Cell Transplantation
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.